Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model

Holly Stessman, Linda B. Baughn, Aaron Sarver, Tian Xia, Raamesh Deshpande, Aatif Mansoor, Susan A. Walsh, John J. Sunderland, Nathan G. Dolloff, Michael A. Linden, Fenghuang Zhan, Siegfried Janz, Chad L. Myers, Brian G. Van Ness

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Multiple myeloma is a hematologic malignancy characterized by the proliferation of neoplastic plasma cells in the bone marrow. Although the first-to-market proteasome inhibitor bortezomib (Velcade) has been successfully used to treat patients with myeloma, drug resistance remains an emerging problem. In this study, we identify signatures of bortezomib sensitivity and resistance by gene expression profiling (GEP) using pairs of bortezomib-sensitive (BzS) and bortezomib-resistant (BzR) cell lines created from the Bcl-XL/Myc double-transgenic mouse model of multiple myeloma. Notably, these BzR cell lines show cross-resistance to the next-generation proteasome inhibitors, MLN2238 and carfilzomib (Kyprolis) but not to other antimyeloma drugs. We further characterized the response to bortezomib using the Connectivity Map database, revealing a differential response between these cell lines to histone deacetylase (HDAC) inhibitors. Furthermore, in vivo experiments using the HDAC inhibitor panobinostat confirmed that the predicted responder showed increased sensitivity to HDAC inhibitors in the BzR line. These findings show that GEP may be used to document bortezomib resistance in myeloma cells and predict individual sensitivity to other drug classes. Finally, these data reveal complex heterogeneity within multiple myeloma and suggest that resistance to one drug class reprograms resistant clones for increased sensitivity to a distinct class of drugs. This study represents an important next step in translating pharmacogenomic profiling and may be useful for understanding personalized pharmacotherapy for patients with multiple myeloma.

Original languageEnglish (US)
Pages (from-to)1140-1150
Number of pages11
JournalMolecular Cancer Therapeutics
Volume12
Issue number6
DOIs
StatePublished - Jun 1 2013
Externally publishedYes

Fingerprint

Multiple Myeloma
Histone Deacetylase Inhibitors
Proteasome Inhibitors
Therapeutics
Gene Expression Profiling
Cell Line
Pharmaceutical Preparations
Bortezomib
Pharmacogenetics
Hematologic Neoplasms
Plasma Cells
Drug Resistance
Transgenic Mice
Clone Cells
Bone Marrow
Databases
Drug Therapy
carfilzomib

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Stessman, H., Baughn, L. B., Sarver, A., Xia, T., Deshpande, R., Mansoor, A., ... Van Ness, B. G. (2013). Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model. Molecular Cancer Therapeutics, 12(6), 1140-1150. https://doi.org/10.1158/1535-7163.MCT-12-1151

Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model. / Stessman, Holly; Baughn, Linda B.; Sarver, Aaron; Xia, Tian; Deshpande, Raamesh; Mansoor, Aatif; Walsh, Susan A.; Sunderland, John J.; Dolloff, Nathan G.; Linden, Michael A.; Zhan, Fenghuang; Janz, Siegfried; Myers, Chad L.; Van Ness, Brian G.

In: Molecular Cancer Therapeutics, Vol. 12, No. 6, 01.06.2013, p. 1140-1150.

Research output: Contribution to journalArticle

Stessman, H, Baughn, LB, Sarver, A, Xia, T, Deshpande, R, Mansoor, A, Walsh, SA, Sunderland, JJ, Dolloff, NG, Linden, MA, Zhan, F, Janz, S, Myers, CL & Van Ness, BG 2013, 'Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model', Molecular Cancer Therapeutics, vol. 12, no. 6, pp. 1140-1150. https://doi.org/10.1158/1535-7163.MCT-12-1151
Stessman, Holly ; Baughn, Linda B. ; Sarver, Aaron ; Xia, Tian ; Deshpande, Raamesh ; Mansoor, Aatif ; Walsh, Susan A. ; Sunderland, John J. ; Dolloff, Nathan G. ; Linden, Michael A. ; Zhan, Fenghuang ; Janz, Siegfried ; Myers, Chad L. ; Van Ness, Brian G. / Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model. In: Molecular Cancer Therapeutics. 2013 ; Vol. 12, No. 6. pp. 1140-1150.
@article{20aa38ddae3c4bedbbbc3fb1446eb30b,
title = "Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model",
abstract = "Multiple myeloma is a hematologic malignancy characterized by the proliferation of neoplastic plasma cells in the bone marrow. Although the first-to-market proteasome inhibitor bortezomib (Velcade) has been successfully used to treat patients with myeloma, drug resistance remains an emerging problem. In this study, we identify signatures of bortezomib sensitivity and resistance by gene expression profiling (GEP) using pairs of bortezomib-sensitive (BzS) and bortezomib-resistant (BzR) cell lines created from the Bcl-XL/Myc double-transgenic mouse model of multiple myeloma. Notably, these BzR cell lines show cross-resistance to the next-generation proteasome inhibitors, MLN2238 and carfilzomib (Kyprolis) but not to other antimyeloma drugs. We further characterized the response to bortezomib using the Connectivity Map database, revealing a differential response between these cell lines to histone deacetylase (HDAC) inhibitors. Furthermore, in vivo experiments using the HDAC inhibitor panobinostat confirmed that the predicted responder showed increased sensitivity to HDAC inhibitors in the BzR line. These findings show that GEP may be used to document bortezomib resistance in myeloma cells and predict individual sensitivity to other drug classes. Finally, these data reveal complex heterogeneity within multiple myeloma and suggest that resistance to one drug class reprograms resistant clones for increased sensitivity to a distinct class of drugs. This study represents an important next step in translating pharmacogenomic profiling and may be useful for understanding personalized pharmacotherapy for patients with multiple myeloma.",
author = "Holly Stessman and Baughn, {Linda B.} and Aaron Sarver and Tian Xia and Raamesh Deshpande and Aatif Mansoor and Walsh, {Susan A.} and Sunderland, {John J.} and Dolloff, {Nathan G.} and Linden, {Michael A.} and Fenghuang Zhan and Siegfried Janz and Myers, {Chad L.} and {Van Ness}, {Brian G.}",
year = "2013",
month = "6",
day = "1",
doi = "10.1158/1535-7163.MCT-12-1151",
language = "English (US)",
volume = "12",
pages = "1140--1150",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model

AU - Stessman, Holly

AU - Baughn, Linda B.

AU - Sarver, Aaron

AU - Xia, Tian

AU - Deshpande, Raamesh

AU - Mansoor, Aatif

AU - Walsh, Susan A.

AU - Sunderland, John J.

AU - Dolloff, Nathan G.

AU - Linden, Michael A.

AU - Zhan, Fenghuang

AU - Janz, Siegfried

AU - Myers, Chad L.

AU - Van Ness, Brian G.

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Multiple myeloma is a hematologic malignancy characterized by the proliferation of neoplastic plasma cells in the bone marrow. Although the first-to-market proteasome inhibitor bortezomib (Velcade) has been successfully used to treat patients with myeloma, drug resistance remains an emerging problem. In this study, we identify signatures of bortezomib sensitivity and resistance by gene expression profiling (GEP) using pairs of bortezomib-sensitive (BzS) and bortezomib-resistant (BzR) cell lines created from the Bcl-XL/Myc double-transgenic mouse model of multiple myeloma. Notably, these BzR cell lines show cross-resistance to the next-generation proteasome inhibitors, MLN2238 and carfilzomib (Kyprolis) but not to other antimyeloma drugs. We further characterized the response to bortezomib using the Connectivity Map database, revealing a differential response between these cell lines to histone deacetylase (HDAC) inhibitors. Furthermore, in vivo experiments using the HDAC inhibitor panobinostat confirmed that the predicted responder showed increased sensitivity to HDAC inhibitors in the BzR line. These findings show that GEP may be used to document bortezomib resistance in myeloma cells and predict individual sensitivity to other drug classes. Finally, these data reveal complex heterogeneity within multiple myeloma and suggest that resistance to one drug class reprograms resistant clones for increased sensitivity to a distinct class of drugs. This study represents an important next step in translating pharmacogenomic profiling and may be useful for understanding personalized pharmacotherapy for patients with multiple myeloma.

AB - Multiple myeloma is a hematologic malignancy characterized by the proliferation of neoplastic plasma cells in the bone marrow. Although the first-to-market proteasome inhibitor bortezomib (Velcade) has been successfully used to treat patients with myeloma, drug resistance remains an emerging problem. In this study, we identify signatures of bortezomib sensitivity and resistance by gene expression profiling (GEP) using pairs of bortezomib-sensitive (BzS) and bortezomib-resistant (BzR) cell lines created from the Bcl-XL/Myc double-transgenic mouse model of multiple myeloma. Notably, these BzR cell lines show cross-resistance to the next-generation proteasome inhibitors, MLN2238 and carfilzomib (Kyprolis) but not to other antimyeloma drugs. We further characterized the response to bortezomib using the Connectivity Map database, revealing a differential response between these cell lines to histone deacetylase (HDAC) inhibitors. Furthermore, in vivo experiments using the HDAC inhibitor panobinostat confirmed that the predicted responder showed increased sensitivity to HDAC inhibitors in the BzR line. These findings show that GEP may be used to document bortezomib resistance in myeloma cells and predict individual sensitivity to other drug classes. Finally, these data reveal complex heterogeneity within multiple myeloma and suggest that resistance to one drug class reprograms resistant clones for increased sensitivity to a distinct class of drugs. This study represents an important next step in translating pharmacogenomic profiling and may be useful for understanding personalized pharmacotherapy for patients with multiple myeloma.

UR - http://www.scopus.com/inward/record.url?scp=84879293601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879293601&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-12-1151

DO - 10.1158/1535-7163.MCT-12-1151

M3 - Article

VL - 12

SP - 1140

EP - 1150

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 6

ER -